Mikhail, Nasser <br/><br/>
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.  [electronic resource] 

 -  Expert opinion on investigational drugs  Jun 2008 
 - 845-53 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1744-7658 
<br/><br/><label>Standard No.: </label>10.1517/13543784.17.6.845  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adamantane--adverse effects<br/>Body Weight--drug effects<br/>Clinical Trials, Phase III as Topic--statistics & numerical data<br/>Diabetes Mellitus, Type 2--blood<br/>Dipeptidyl Peptidase 4<br/>Dipeptidyl-Peptidase IV Inhibitors--adverse effects<br/>Double-Blind Method<br/>Drug Therapy, Combination<br/>Exenatide<br/>Glucagon-Like Peptide 1--pharmacokinetics<br/>Glucagon-Like Peptide-1 Receptor<br/>Glycated Hemoglobin--analysis<br/>Humans<br/>Hypoglycemia--chemically induced<br/>Hypoglycemic Agents--adverse effects<br/>Incretins--physiology<br/>Insulin--metabolism<br/>Insulin Secretion<br/>Nausea--chemically induced<br/>Nitriles--adverse effects<br/>Peptides--adverse effects<br/>Pyrazines--adverse effects<br/>Pyrrolidines--adverse effects<br/>Randomized Controlled Trials as Topic<br/>Receptors, Glucagon--drug effects<br/>Sitagliptin Phosphate<br/>Triazoles--adverse effects<br/>Venoms--adverse effects<br/>Vildagliptin<br/>Vomiting--chemically induced